Description
Summary Abstract
Compound 7P (2-[(2-methoxyphenyl)[(4-methylphenyl)sulfonyl]amino]-N-(4-methoxy-3-pyridinyl)acetamide; CAS 1890208-58-8) is a synthetic small molecule identified as a thromboxane (TX) receptor antagonist and prostacyclin synthase (prostaglandin I2 synthase, PTGIS/CYP8A1)-selective inhibitor with preferential activity over thromboxane synthase (CYP5A1). Its primary research context is central nervous system (CNS) axon regeneration: in cultured primary neurons from hippocampus, cerebral cortex, and retina, Compound 7P promotes neurite outgrowth, and in an optic nerve injury animal model it induced growth of GAP-43-positive axons in vivo — demonstrating translational activity from in vitro signaling to axonal regeneration. The compound has also been studied for effects on monoaminergic neurotransmission, cognition, and mood in preclinical models.
Clinical Indications
Compound 7P is investigated across CNS and neuroinflammatory research applications:
- Axon Regeneration: Induced growth of GAP-43-positive axons in an optic nerve crush injury model, indicating in vivo translational potential for CNS regeneration research programs.
- Neurite Outgrowth: Promoted neurite extension in primary neuron cultures from hippocampus, cerebral cortex, and retina, supporting mechanistic dissection of regeneration-associated pathways (epigenetic, mTOR, STAT3).
- Cognitive and Mood Research: Investigated for modulation of serotonin and dopamine neurotransmitter systems in preclinical models of memory, concentration, and mood regulation.
Contraindications
- Eicosanoid Pathway Studies: As a TX receptor antagonist and PTGIS modulator, Compound 7P will alter prostanoid signaling in any model where thromboxane A2 or prostacyclin I2 are relevant mediators; control conditions must account for this.
- Platelet Aggregation Models: Thromboxane receptor antagonism affects platelet activation; studies involving thrombosis or hemostasis endpoints require careful interpretation of Compound 7P’s pharmacology.
- Monoamine Endpoint Assays: Monoaminergic neurotransmitter modulation reported for this compound may confound behavioral endpoints if not distinguished from the primary prostanoid mechanism.
Mechanism of Action (MOA)
Compound 7P engages multiple targets relevant to CNS regeneration and neuroplasticity:
Thromboxane Receptor Antagonism
Compound 7P antagonizes the thromboxane (TP) receptor, blocking TXA2-mediated downstream signaling. TP receptor activation inhibits neurite outgrowth and promotes growth cone collapse; its antagonism removes a key brake on axonal extension and neuroplastic remodeling.
PTGIS-Selective Synthase Inhibition
The compound preferentially inhibits prostaglandin I2 synthase (PTGIS/CYP8A1) over thromboxane synthase (CYP5A1), shifting prostanoid balance and altering the TXA2:PGI2 ratio. This selectivity profile produces distinct signaling consequences from non-selective cyclooxygenase inhibition.
GAP-43-Positive Axon Growth In Vivo
In an optic nerve crush model, systemic Compound 7P administration induced growth of GAP-43-positive axons — a well-validated marker of active axonal regeneration — confirming that the in vitro neurite activity translates to in vivo anatomical regeneration. Relevant intracellular pathways include epigenetic transcriptional de-repression, mTOR, and STAT3 signaling.
Monoaminergic Modulation
Secondary pharmacology encompasses modulation of serotonin and dopamine neurotransmitter pathways in preclinical behavioral models, though the precise binding targets and the relationship between prostanoid and monoaminergic effects require further mechanistic delineation.
Key Features & Specifications
Compound 7P is supplied as an encapsulated preparation for CNS regeneration and neuroplasticity research:
Chemical Analysis
| Property | Specification Reference Data |
|---|---|
| IUPAC Name | 2-[(2-methoxyphenyl)[(4-methylphenyl)sulfonyl]amino]-N-(4-methoxy-3-pyridinyl)acetamide |
| CAS Number | 1890208-58-8 |
| Molecular Formula | C22H23N3O5S |
| Molecular Weight | 441.5 g/mol |
| PubChem CID | 252827453 |
| Synonyms | Compound 7P; acetamide 2-[(2-methoxyphenyl)[(4-methylphenyl)sulfonyl]amino]-N-(4-methoxy-3-pyridinyl) |
| Form / Variation | Capsules (SKU C-009, $54.00) |
Storage, Safety, and Handling
Storage Protocol
Store capsules at −20 °C in a sealed, moisture-protected container away from direct light. Compound 7P is a sulfonamide-containing small molecule; stability data in aqueous buffers should be confirmed by the end user. For solution-based assays, dissolve in DMSO and dilute into aqueous media immediately prior to use.
Handling & Compliance
Handle with standard PPE. Compound 7P has no approved pharmaceutical indication and is not currently scheduled as a controlled substance. WADA classification has not been specifically assigned. Institutional biosafety protocols for small-molecule CNS research compounds should be followed.